Understanding Cholesterol

Understanding Cholesterol

---

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention. These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

---

In Brief

Cholesterol is essential. The body cannot function without it. The problem isn’t cholesterol itself — it’s the delivery system.

Cardiovascular risk tracks most closely with how many atherogenic (plaque-forming) particles circulate in the blood, and for how long, not with how much cholesterol those particles happen to be carrying on any given day. Standard lipid panels report LDL cholesterol (the amount of cholesterol inside LDL particles). ApoB counts the particles themselves.

Most of the time these two measurements track together. In specific contexts — insulin resistance, elevated triglycerides, metabolic syndrome, type 2 diabetes — they diverge, and LDL-C alone can understate risk.

Atherosclerosis develops over decades. Early arterial changes are common by young adulthood, and clinical events typically follow many years of silent progression. Reducing particle burden over time slows progression and helps stabilize existing plaque. The earlier this is addressed, the more disease is prevented.

The Core Paradox

In a study of 136,905 patients hospitalized with coronary artery disease, nearly half had LDL-C below 100 mg/dL on admission. (1) Their cholesterol looked acceptable. They had heart attacks anyway.

Part of the explanation is technical — lipid levels can fall during acute illness, so admission values don’t always reflect baseline. (2) But the deeper point holds: standard cholesterol testing measures how much cholesterol is being carried in the blood. Cardiovascular risk tracks more closely with how many atherogenic particles are circulating, and for how long. (3)

Why the Same LDL-C Can Mean Different Things

Consider two people, both with an LDL-C of 130 mg/dL. The numbers below are illustrative only, intended to show how particle count can diverge from cholesterol content. They are not clinical thresholds.

Person	LDL-C	Particle Size	Estimated ApoB	Particle Count
Person A	130 mg/dL	Fewer, larger particles	~80s mg/dL	Modest
Person B	130 mg/dL	Many smaller particles	~120s mg/dL	High

Same LDL-C. Very different particle counts. Very different cardiovascular risk over time.

The reason particle count matters biologically: atherosclerosis is driven by particles entering the artery wall and becoming trapped, not by cholesterol floating in the bloodstream. More particles means more entry attempts, more retention, more inflammation, more plaque. The process accumulates over decades. What matters is cumulative exposure — the total particle burden across a lifetime. (3)

Each atherogenic particle carries a protein called apolipoprotein B (ApoB), one per particle. Measuring ApoB counts these particles directly. This is the central concept the rest of this series builds on.

When Discordance Occurs

The Person B pattern — many smaller, cholesterol-depleted LDL particles — is common in insulin resistance, elevated triglycerides, metabolic syndrome, and type 2 diabetes. (3) The cholesterol value can look acceptable even while the number of particles remains high.

Discordance between LDL-C and ApoB is not uncommon. In the Women’s Health Study cohort of nearly 28,000 healthy women, around 19% showed meaningful disagreement between the two measures. (20)

For people without these metabolic features, LDL-C remains a reasonable proxy for particle number and a useful clinical signal. The issue is specific: in identifiable contexts, LDL-C alone understates risk.

What Cholesterol Actually Is

Cholesterol is often discussed as though it were a toxin — a substance to be minimized, avoided, or eliminated. This framing affects how people interpret cholesterol results, food choices, and treatment decisions, and it sets up disappointment when numbers don’t respond the way the mental model predicts.

But cholesterol is not a toxin. It is a molecule the body cannot function without.

Essential Functions of Cholesterol

Function	Why It Matters
Cell membrane structure	Every cell membrane contains cholesterol; without it, membranes lose integrity
Brain function	The brain contains roughly a quarter of the body’s total cholesterol, supporting myelin and synaptic function (5)
Hormone synthesis	Every steroid hormone (cortisol, aldosterone, testosterone, estrogen, progesterone) begins as a cholesterol molecule (6)
Vitamin D synthesis	When sunlight reaches the skin, a cholesterol derivative is converted into vitamin D
Digestion	The liver converts cholesterol into bile acids, enabling absorption of dietary fats and fat-soluble vitamins (6)

These are not minor functions. The goal of cholesterol management is not elimination. It is preventing the delivery system from causing harm.

Why Dietary Cholesterol Has a Limited Effect

Given how essential cholesterol is, the body doesn’t leave supply to chance.

On a typical Western diet, an adult consumes about 300–400 mg of cholesterol per day from food. The liver secretes roughly 700–1,000 mg per day into the intestine through bile, most of which is reabsorbed. (7,8) Internal recycling dwarfs dietary intake.

For most people, dietary cholesterol has a modest effect on blood LDL-C because endogenous synthesis and intestinal absorption adjust to maintain supply. (7,8) Absorption efficiency also varies widely between individuals, from roughly 20% to 80%. (9)

The practical result: one person can eat eggs daily and have normal cholesterol. Another can avoid dietary cholesterol entirely and still have elevated LDL-C. Diet matters, but rarely in the simple input-output way people expect.

For most people, saturated fat intake has a larger effect on blood LDL-C than dietary cholesterol itself. (15) Refined carbohydrates and excess alcohol also influence the broader lipid profile, particularly triglycerides.

If LDL-C didn’t drop after cutting dietary cholesterol, that often reflects normal regulatory biology rather than failed effort. Article 3 covers this in detail.

How Atherosclerosis Develops

Before turning to the particles themselves and what testing measures, it is worth understanding what they do. The purpose of lipid management is reducing the likelihood that this disease process progresses, accelerates, or causes a clinical event over time.

Timeline

Atherosclerosis develops over decades.

The PDAY study (Pathobiological Determinants of Atherosclerosis in Youth) examined coronary arteries from young people who died of accidents and found that fatty streaks were common in teenagers, with raised lesions increasing progressively through the second, third, and fourth decades of life. (16)

By the time most people first discuss cholesterol with a clinician, the disease process has typically been underway for years. Early lesions can regress, and the arterial changes seen in youth are not irreversible.

Prevention is not preventing something that might begin someday. It is influencing a process that has likely already begun. The earlier particle burden is addressed, the more atherosclerosis can be prevented or slowed. (3)

What Happens Inside the Artery Wall

LDL particles do not passively leak into the artery wall. They cross the inner lining (the endothelium) through an active cellular process, and once inside, ApoB-containing particles can bind to proteoglycans in the arterial wall, contributing to their retention. (23)

This is why ApoB matters mechanistically — not just as a marker that allows particles to be counted, but as the protein involved in the retention process itself. More ApoB-carrying particles in circulation means more particles arriving at the wall, and more particles retained there once they arrive.

Once trapped, particles undergo chemical changes (including oxidation) that trigger an immune response. Immune cells engulf the modified particles and become “foam cells.” Inflammation follows. Smooth muscle cells migrate in. Over time, a plaque forms: a lipid-rich core covered by a fibrous cap.

Plaque Rupture

A heart attack happens when a plaque becomes unstable and ruptures or erodes, exposing its contents to the bloodstream and triggering clot formation. If the clot blocks the artery, blood flow stops, and heart muscle begins to die.

Plaque size alone does not predict rupture. Many heart attacks arise from plaques that had not severely narrowed the artery beforehand, although severely narrowed plaques contribute as well. (17) What matters is plaque stability: the thickness of the fibrous cap, the degree of inflammation within the plaque, and the activity of enzymes that degrade the cap. (17)

A person can feel completely well until the moment a plaque becomes unstable.

Burden and Vulnerability

Cardiovascular risk has two components:

Component	What It Means	Primary Drivers	Why It Matters
Plaque burden	How much atherosclerosis exists	Cumulative ApoB particle exposure over time	More plaque means more total at-risk surface area
Plaque vulnerability	How likely a plaque is to trigger an event	Inflammation, thrombosis tendency, cap integrity	Vulnerable plaques can rupture even when narrowing is only moderate

This is why stenting a tight coronary narrowing relieves symptoms but does not eliminate future heart attack risk. Events arise from plaque biology throughout the coronary tree, not only from the tightest lesion. (17)

Reducing particle burden over time slows plaque progression and helps stabilize existing plaques. Fewer particles entering artery walls means less accumulation and less inflammation, addressing both burden and vulnerability. (3)

How Cholesterol Travels Through the Blood

Cholesterol is fat-soluble. Blood is mostly water. To move cholesterol through the bloodstream, the body packages it inside spherical particles called lipoproteins — water-compatible on the outside and fat-compatible on the inside.

Different lipoproteins have different jobs. For understanding cardiovascular risk, one protein on these particles matters most: ApoB.

Lipoprotein	Primary Cargo	Carries ApoB?	Atherogenic?
LDL	Cholesterol	Yes (one per particle)	Yes
VLDL	Triglycerides	Yes (one per particle)	Yes (including remnants)
Lp(a)	Cholesterol	Yes (one per particle)	Yes
Chylomicrons	Dietary triglycerides	Yes (ApoB-48)	Parent particles: no (too large). Remnants: yes
HDL	Cholesterol flux	No	No

ApoB: The Protein That Counts

The particles that drive atherosclerosis are the ApoB-containing particles: LDL, VLDL (and its remnants), and Lp(a). Each carries one ApoB protein per particle. Clinically measured ApoB reflects predominantly ApoB-100 particles in fasting samples, so a single ApoB number functions as a count of the atherogenic particle pool most relevant to cardiovascular disease. (3)

Chylomicrons also carry ApoB (in the ApoB-48 form), but they are generally too large to enter the artery wall. The atherogenic concern is their remnants, not the parent particles.

HDL does not carry ApoB, which is why HDL biology differs fundamentally from the particles that drive atherosclerosis.

When a standard lipid panel reports LDL-C, it is measuring the cholesterol content of LDL particles. When ApoB is measured, it counts the particles themselves. Particle count is what the artery wall actually responds to over time.

LDL: The Delivery System That Can Become a Problem

LDL particles deliver cholesterol from the liver to cells throughout the body. Every cell needs cholesterol, and LDL is the primary delivery system. Under normal circumstances, LDL particles circulate, deliver their cargo, and are cleared by the liver. The system works.

The problem arises when too many LDL particles circulate for too long. When particle numbers stay elevated, some particles enter the walls of arteries, particularly where blood flow is disturbed or the arterial lining is stressed. Once inside the artery wall, particles can become trapped and trigger the inflammatory cascade described above. (3)

The LDL Receptor: Why Genetics Matters

The liver clears LDL particles from the bloodstream through a structure called the LDL receptor. The receptor sits on the surface of liver cells, binds passing LDL particles, and pulls them inside, where the cholesterol is recycled and the particle is broken down.

The number of working LDL receptors on a person’s liver cells largely determines how efficiently LDL is cleared and, therefore, how high LDL-C runs.

This is why genetics matters so much. People with familial hypercholesterolemia inherit fewer functional LDL receptors and clear LDL more slowly, which is why their LDL-C can be markedly elevated from childhood despite a healthy diet. (22)

Statins lower hepatic cholesterol synthesis, which increases LDL receptor activity and improves LDL clearance in most patients. (15) PCSK9 inhibitors work by preventing the receptor from being destroyed prematurely, allowing more clearance per cell. (3)

Understanding the receptor turns several otherwise mysterious facts into one mechanism: why genetics dominates baseline LDL-C, why statins work, why a small number of people respond poorly to them, and why a separate medication class exists for very-high-risk patients.

VLDL: Where Triglycerides and Particle Count Connect

Triglycerides matter partly because they often signal changes in the overall particle environment, particularly in insulin resistance and metabolic syndrome.

Triglycerides travel mainly inside VLDL particles. The liver packages triglycerides into VLDL and releases them into the bloodstream. As VLDL circulates, it delivers triglycerides to tissues. As VLDL releases its triglyceride cargo, what is left behind is a smaller, cholesterol-enriched particle called a remnant.

Remnants still carry ApoB and, like LDL, can still enter the artery wall. Some remnants convert further to LDL; others are cleared by the liver earlier. Each particle carries one ApoB throughout its life. (3)

Elevated triglycerides typically reflect increased VLDL traffic and, in insulin-resistant states, a higher overall ApoB particle burden. (3,10) In insulin resistance, higher triglycerides commonly accompany smaller, cholesterol-depleted LDL particles — and a lot of them. (3)

When LDL particles are smaller, the same LDL-C number can hide a substantially larger particle count. The test looks fine. The particle burden is elevated. The arterial exposure continues to accumulate regardless of what the lipid panel reports.

Lp(a): The Inherited Risk Factor

Lp(a), pronounced “L-P-little-a,” is an LDL-like particle with an additional protein called apolipoprotein(a) attached. Like LDL, it carries ApoB and can enter the artery wall. But Lp(a) causes harm through multiple pathways: promoting inflammation, interfering with clot breakdown, and accelerating plaque formation. (3,11)

What makes Lp(a) distinctive is that the level is largely genetic — more than 90% heritable. (11) Unlike LDL-C, Lp(a) does not respond meaningfully to diet or exercise. Standard statins do not lower it and may slightly increase it on average. (11)

Levels are stable for life, which is why one measurement provides lifetime information.

Elevated Lp(a) is common. Roughly 10–20% of adults have levels in the range considered clinically meaningful, depending on the threshold and population studied, yet most people have never had it measured because standard panels don’t include it. (11)

For someone with elevated Lp(a), cumulative arterial exposure begins earlier and accumulates faster than the standard lipid panel suggests. Article 2 covers Lp(a) in depth.

HDL: More Complicated Than “Good Cholesterol”

HDL behaves differently from ApoB-containing particles, which is why “good cholesterol” is more complicated than many people assume.

HDL particles participate in moving cholesterol from tissues back toward the liver, a process called reverse cholesterol transport. In theory, this should be protective. But HDL biology is complex. Clinical trials of medications that raise HDL-C (niacin, CETP inhibitors) have not produced the cardiovascular benefits expected. (12,13)

What a standard panel reports as HDL-C is the cholesterol content carried in HDL particles, not a measure of how well those particles function.

The practical takeaway: low HDL-C is a useful warning signal because it often reflects insulin resistance, metabolic syndrome, or other cardiometabolic problems worth addressing. The HDL number itself is not a treatment target. Improving metabolic health tends to raise HDL-C, but the benefit comes from the metabolic improvement, not from the HDL number itself.

What the Standard Lipid Panel Measures

A standard lipid panel typically reports four to five numbers:

Test	What It Measures	What It Does NOT Tell You
Total cholesterol	All cholesterol across all particles	Doesn’t distinguish particle types
LDL-C	Cholesterol content in LDL particles	Doesn’t count particles
HDL-C	Cholesterol content in HDL particles	Doesn’t reflect HDL function
Triglycerides	Triglyceride fat in blood	A single measurement may not reflect typical level
Non-HDL-C	Total cholesterol minus HDL-C	Better than LDL-C when TG elevated, but still measures content

Technical Points That Matter

LDL-C is usually calculated, not measured. Most labs use the Friedewald equation to estimate LDL-C from the other values. (14) The calculation becomes less reliable as triglycerides rise. Modern equations (Martin/Hopkins, Sampson) improve accuracy at elevated triglyceride levels, but no calculation captures particle number.

Non-HDL-C is more useful than it gets credit for. It captures cholesterol carried in all atherogenic particles (LDL, VLDL, remnants, and Lp(a)) rather than LDL alone. When triglycerides are elevated, non-HDL-C often reflects atherogenic burden better than LDL-C. (15) It is already on every standard panel and costs nothing extra to interpret.

HDL-C is not HDL function. A high HDL-C number does not guarantee that HDL particles are working effectively.

When LDL-C and Particle Number Disagree

LDL-C and ApoB often track together. When they do, LDL-C is a reasonable proxy for cardiovascular risk. When they diverge — discordance — ApoB is generally the closer signal of risk over time. (3)

Condition	What Happens at the Particle Level	LDL-C Appearance	Actual Particle Burden
Elevated triglycerides	LDL particles smaller, each carrying less cholesterol	Often acceptable	Elevated
Insulin resistance / metabolic syndrome	More small dense LDL; higher TG, lower HDL-C	Often “normal”	Elevated
Type 2 diabetes	Same pattern as insulin resistance	Often “fine”	Elevated

This is one reason some patients present with coronary disease despite “normal” LDL-C. (1,3) It is the most clinically important pattern in modern lipidology, and it is invisible on a standard panel.

This does not mean LDL-C is useless. For people without these metabolic features, LDL-C and ApoB usually track together, and the standard panel provides useful information. The issue is specific: in identifiable contexts, LDL-C alone understates risk.

What Shapes Cholesterol Levels

Cholesterol levels reflect a mix of factors that can be modified and factors that cannot.

Factor	Modifiable?	Effect on Lipids
Dietary cholesterol	Yes	Modest for most people; synthesis and absorption adjust (7,8)
Saturated fat / refined carbs	Yes	Larger effect on LDL-C and overall lipid profile (15)
Fructose / HFCS	Yes	Raises triglycerides and ApoB (10)
Insulin sensitivity	Yes	Improving it lowers TG, raises HDL-C, reduces discordance (3)
Physical activity	Yes	Improves lipid patterns independently of weight loss
Sleep	Yes	Sleep disruption associated with adverse cardiometabolic patterns
Smoking	Yes	Worsens lipid profile; quitting helps
Genetics	No	Can dramatically affect production or clearance
Age	No	LDL-C tends to rise with age
Sex and hormones	No	Women: higher HDL-C pre-menopause; LDL-C rises post-menopause
Medical conditions	Partly	Thyroid, kidney, liver disease affect lipids

Article 3 covers lifestyle approaches in detail.

The Interaction Between Genetics and Lifestyle

Some people follow an optimal diet, exercise regularly, and maintain a healthy weight — yet still have elevated LDL because their genetics favor high production or slow clearance. For these individuals, medication is not a failure of willpower. It is a rational response to biology.

Others carry genetic patterns that allow more flexibility without dramatically elevated numbers.

Population-level advice is built on averages. Individual response depends on genetics and metabolic state, and can usually only be determined by tracking results over time.

Why Understanding Matters

The reason this matters is practical. Treatment for cardiovascular risk depends on staying on it long enough to benefit, and that depends partly on whether the rationale for treatment makes sense to the person taking it.

Many people think cholesterol works like grease clogging a pipe. That mental model leads to oversimplified solutions and frustration when numbers don’t respond as expected. It also leaves patients vulnerable to the most common failure mode in lipid management: stopping treatment because numbers look fine, or because the rationale for treatment never quite landed.

The Adherence Problem

Statins, the most commonly prescribed lipid-lowering medications, have a substantial adherence problem. Real-world discontinuation rates vary considerably depending on the population, length of follow-up, and methodology. One large primary-care cohort found that 12% of statin initiators stopped within the first year, (19) and rates rise meaningfully over longer follow-up. Sustained adherence over many years is more the exception than the rule.

A meaningful share of reported statin side effects appears to reflect the nocebo effect: symptoms produced by the expectation of harm rather than by the drug itself. In the ASCOT-LLA trial, muscle-related adverse events occurred at similar rates in statin and placebo groups during the blinded phase, but rose substantially in the open-label extension once patients knew they were taking a statin. (18)

Statin side effects, however, are not imaginary. Some patients experience genuine pharmacologic side effects (myalgia, new-onset diabetes in predisposed individuals, rare elevations in liver enzymes) that require dose adjustment, medication changes, or alternative therapies. The clinical task is distinguishing pharmacologic side effects from nocebo-driven symptoms. Both deserve attention; the responses differ. Article 4 covers this nuance in detail.

The broader pattern across cardiovascular medicine is consistent: people who understand why a treatment matters tend to follow through over the long timeframes the disease actually operates on. Current guidelines, including the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, increasingly emphasize earlier identification and management of dyslipidemia to reduce cumulative exposure to atherogenic lipoproteins over time. (21)

Common Questions

“Why is my cholesterol high when I eat healthy?”

The body produces cholesterol based largely on genetics. (7) Some people cannot reach optimal particle levels through diet alone. This is biology, not personal failure.

“Do I need medication if I eat perfectly?”

Possibly. Diet and lifestyle are foundational, but some people cannot achieve adequate risk reduction through lifestyle alone because of genetics. Medications are tools; their use reflects biology and risk profile, not character.

“My LDL-C is fine but my doctor wants more testing. Why?”

Some clinical features — elevated triglycerides, metabolic syndrome, diabetes, a family history of premature heart disease, or risk that seems higher than the lipid panel suggests — make discordance between LDL-C and particle number more likely. In those contexts, ApoB, Lp(a), or imaging often clarifies the picture.

“If atherosclerosis started in my twenties, is it too late?”

No. Early lesions can regress, plaques can stabilize, and reducing particle burden at any age slows further accumulation. (3) The earlier in life this happens, the more disease is prevented — but “earlier than now” is the version that applies to most adults.

“My HDL is high. Doesn’t that protect me?”

A high HDL-C number is not a guarantee of protection. Trials raising HDL-C with niacin and CETP inhibitors did not reduce cardiovascular events. (12,13) HDL-C is more useful as a marker of metabolic health than as a treatment target on its own.

The Bottom Line

Cholesterol is essential. The body produces it in large quantities because it is required for survival. The goal is not elimination. It is preventing the delivery system from causing harm over decades.

The standard cholesterol test measures how much cholesterol is being carried. Cardiovascular risk tracks more closely with cumulative exposure to ApoB-containing particles. When cholesterol content and particle count diverge — as they often do in insulin resistance, type 2 diabetes, and elevated triglycerides — the standard test understates risk.

Atherosclerosis develops over decades, with early arterial changes common by young adulthood. Heart attacks frequently arise from plaque that becomes unstable and ruptures, not exclusively from the tightest blockages. Reducing particle burden over time slows plaque progression and helps stabilize existing plaque.

For most people, a standard lipid panel provides useful information. For some — those with metabolic syndrome, diabetes, a family history of premature heart disease, or risk that seems out of proportion to standard numbers — ApoB and Lp(a) testing add genuine clarity.

Understanding this biology will not change your genetics. But it can change your decisions, your conversations with your clinician, and the trajectory of your cardiovascular risk over the years ahead.

Next: Article 2 covers how to interpret your lipid panel, when ApoB and Lp(a) testing add value, and what imaging tests reveal about atherosclerosis that blood tests cannot.

Key Terms

Atherogenic: Capable of contributing to atherosclerosis. LDL, VLDL remnants, and Lp(a) are atherogenic because they carry ApoB and can enter artery walls.

ApoB (apolipoprotein B): A protein carried by LDL, VLDL, and Lp(a) particles, one per particle. Measuring ApoB counts atherogenic particles directly.

LDL-C: The cholesterol content of LDL particles; what standard tests report. Does not directly reflect particle number.

VLDL: Very-low-density lipoprotein. Transports triglycerides from the liver; carries ApoB. Some VLDL particles become LDL; others are cleared as remnants.

Lp(a): An LDL-like particle with apolipoprotein(a) attached. Levels are genetically determined and stable for life. Not measured on standard panels.

Discordance: When LDL-C and particle number disagree. Common in insulin resistance, metabolic syndrome, and elevated triglycerides.

Non-HDL-C: Total cholesterol minus HDL-C. Captures cholesterol across all atherogenic particles. Already on every standard panel.

Atherosclerosis: The disease process in which atherogenic particles accumulate within artery walls, forming plaques that can narrow arteries or rupture.

Plaque stability: How likely a plaque is to rupture. Determined by cap thickness, inflammation, and enzymatic activity.

Cumulative exposure: The total particle burden over time. The central driver of plaque burden; what long-term lipid management aims to reduce.

Nocebo effect: When the expectation of harm produces the experience of harm.

References

1. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an American Heart Association Get With The Guidelines database. Am Heart J. 2009;157(1):111–117.

2. Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol. 1993;22(3):933–940.

3. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287–1295.

4. Nes WD. Biosynthesis of cholesterol and other sterols. Chem Rev. 2011;111(10):6423–6451.

5. Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004;24(5):806–815.

6. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34(10):1637–1659.

7. Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21(4):225–245.

8. Jesch ED, Carr TP. Dietary cholesterol: from physiology to cardiovascular risk. Br J Nutr. 2011;106(1):6–14.

9. Bosner MS, Lange LG, Stenson WF, Ostlund RE Jr. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res. 1999;40(2):302–308.

10. Stanhope KL, Bremer AA, Medici V, et al. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab. 2011;96(10):E1596–E1605.

11. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–3946.

12. AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267.

13. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–2099.

14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.

15. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082–e1143.

16. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999;281(8):727–735.

17. Arbab-Zadeh A, Fuster V. From detecting the vulnerable plaque to managing the vulnerable patient: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(12):1582–1593.

18. Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA). Lancet. 2017;389(10088):2473–2481.

19. Halava H, Huupponen R, Pentti J, et al. Predictors of first-year statin medication discontinuation: a cohort study. J Clin Lipidol. 2016;10(4):987–995.

20. Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129(5):553–561.

21. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2025.11.016.

22. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29(4):431–438.

23. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551–561.